Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Other3

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT04443322Not ApplicableUnknown
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
Liver CarcinomaLiver Transplant; Complications
PrincipalinvestigatorStart date: 2020-09-19
NCT04425226Not ApplicableUnknown
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
Hepatocellular Carcinoma RecurrentLiver Transplant; Complications
PrincipalinvestigatorStart date: 2020-08-06

Research Network

Collaboration Network

7 collaborators·7 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Qiang Xia, MD., Ph.D.

Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Related
1 trials

Shared therapeutic areas:

Hepatocellular Carcinoma RecurrentLiver Transplant; Complications

Worked with same sponsors:

RenJi Hospital
Collaborated on 1 trial
Similarity Score24%

Qiang Xia, MD

Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Related
1 trials

Shared therapeutic areas:

Liver CarcinomaLiver Transplant; Complications

Worked with same sponsors:

RenJi Hospital
Collaborated on 1 trial
Similarity Score24%

Jian-jun Zhang, MD

Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Related
1 trials

Shared therapeutic areas:

Liver CarcinomaLiver Transplant; Complications

Worked with same sponsors:

RenJi Hospital
Collaborated on 1 trial
Similarity Score24%

Qiang Xia, Prof. MD

Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Related
3 trials

Shared therapeutic areas:

Fibrosis, Liver

Worked with same sponsors:

RenJi Hospital
Collaborated on 1 trial
Similarity Score14%

Hamid Gourabi, PhD

head of Royan Institute

Related
52 trials

Shared therapeutic areas:

Fibrosis, Liver
Similarity Score8%

Tao HAN, MD

Tianjin Third Central Hospital

Related
1 trials

Shared therapeutic areas:

Fibrosis, Liver
Similarity Score8%

Jidong Jia, MD

Beijing Friendship Hospital

Related
2 trials

Shared therapeutic areas:

Fibrosis, Liver
Similarity Score8%

Xiaozhong WANG, MD

Hospital of Chinese Medicine of the Xinjiang Uygur Autonomous Region

Related
1 trials

Shared therapeutic areas:

Fibrosis, Liver
Similarity Score8%

John Magee, MD

University of Michigan Medical Center, Ann Arbor

Related
3 trials

Shared therapeutic areas:

Fibrosis, Liver
Similarity Score8%

Karim Boudjema, MD, PhD

Rennes University Hospital

Related
6 trials

Shared therapeutic areas:

Fibrosis, Liver
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT04443322Not ApplicablePrincipalInvestigator

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

Liver CarcinomaLiver Transplant; Complications
Unknown
NCT04425226Not ApplicablePrincipalInvestigator

Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant

Hepatocellular Carcinoma RecurrentLiver Transplant; Complications
Unknown
NCT05926778PrincipalInvestigator

Multiomics Study of Fibrosis Factors After Liver Transplantation and Exploration of Fibrosis Methylation Biomarkers

Liver Fibrosis
Unknown

All 3 trials loaded